[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) – Form 4 Insider Filing

On 26 June 2025, non-employee director Troy A. Ignelzi reported the grant of 14,750 stock options under the company’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program. The options carry an exercise price of $4.01 per share, expire on 25 June 2035, and will vest in full on the earlier of 26 June 2026 (one-year anniversary) or the next annual shareholders’ meeting, subject to continued board service.

The filing shows no disposition of shares; it solely reflects an automatic annual equity grant to a board member. Following the grant, Ignelzi beneficially owns 14,750 derivative securities (options) and no change in direct common-stock ownership was reported.

Because this is a routine director compensation grant rather than an open-market purchase or sale, the event is generally viewed as neutral from a market-moving perspective.

Insights

Financial Analyst

TL;DR: Routine option grant to CTNM director; neutral market impact.

The Form 4 details a standard annual equity award—14,750 options at $4.01—granted to director Troy Ignelzi. Vesting over one year (or next AGM) aligns with common governance practice for biotech boards. No shares were bought or sold on the open market, so there is neither bullish buying signal nor insider selling pressure. With less than 0.1% potential dilution and no cash outlay, this filing is immaterial to valuation or liquidity. Investors may note the relatively low strike price, which merely reflects recent trading levels rather than management’s view. Overall, the disclosure is procedural and does not alter CTNM’s investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ignelzi Troy A.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.01	06/26/2025		A		14,750		(1)	06/25/2035	Class A Common Stock	14,750	$0	14,750	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CTNM options did Troy A. Ignelzi receive on 26 June 2025?

14,750 stock options were granted under the 2024 Equity Incentive Plan.

What is the exercise price of the newly granted CTNM options?

The options are exercisable at $4.01 per share.

When will the CTNM options granted to Director Ignelzi vest?

They vest in full on the earlier of 26 June 2026 or the next annual meeting of shareholders.

Does the Form 4 indicate any open-market purchase or sale of CTNM common stock?

No. The filing reflects a routine option grant; no shares were bought or sold.

What is the expiration date of the granted CTNM stock options?

The options expire on 25 June 2035.